Hammond, J. et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19. N. Engl. J. Med. 386, 1397–1408. https://doi.org/10.1056/NEJMoa2118542 (2022).
Gottlieb, R. L. et al. Early remdesivir to forestall development to extreme covid-19 in outpatients. N. Engl. J. Med. 386, 305–315. https://doi.org/10.1056/NEJMoa2116846 (2022).
RECOVERY Collaborative Group et al. Dexamethasone in hospitalized sufferers with covid-19. N. Engl. J. Med. 384, 693–704. https://doi.org/10.1056/NEJMoa2021436 (2021).
The Writing Committee for the REMAP-CAP Investigators. Impact of hydrocortisone on mortality and organ assist in sufferers with extreme COVID-19: The remap-cap COVID-19 corticosteroid area randomized medical trial. JAMA 324, 1317–1329. https://doi.org/10.1001/jama.2020.17022 (2020).
Cano, E. J. et al. Influence of corticosteroids in coronavirus illness 2019 outcomes: Systematic overview and meta-analysis. Chest 159, 1019–1040. https://doi.org/10.1016/j.chest.2020.10.054 (2021).
REMAP-CAP Investigators et al. Interleukin-6 receptor antagonists in critically unwell sufferers with covid-19. N. Engl. J. Med. 384, 1491–1502. https://doi.org/10.1056/NEJMoa2100433 (2021).
Kalil, A. C. et al. Baricitinib plus remdesivir for hospitalized adults with covid-19. N. Engl. J. Med. 384, 795–807. https://doi.org/10.1056/NEJMoa2031994 (2021).
Chen, P. et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with covid-19. N. Engl. J. Med. 384, 229–237. https://doi.org/10.1056/NEJMoa2029849 (2021).
Weinreich, D. M. et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with covid-19. N. Engl. J. Med. 384, 238–251. https://doi.org/10.1056/NEJMoa2035002 (2021).
COVID-19 Therapy Pointers Panel. Assertion on Tixagevimab Plus Cilgavimab (Evusheld) as Pre-Publicity Prophylaxis of COVID-19. Coronavirus Illness (COVID-19) Therapy Pointers (2023, accessed 4 Apr 2023). https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-evusheld/.
Janiaud, P. et al. Affiliation of convalescent plasma therapy with medical outcomes in sufferers with COVID-19: A scientific overview and meta-analysis. JAMA 325, 1185–1195. https://doi.org/10.1001/jama.2021.2747 (2021).
Joyner, M. J. et al. Convalescent plasma antibody ranges and the chance of dying from covid-19. N. Engl. J. Med. 384, 1015–1027. https://doi.org/10.1056/NEJMoa2031893 (2021).
FDA Information Launch. FDA points emergency use authorization for convalescent plasma as potential promising COVID–19 therapy, one other achievement in administration’s combat towards pandemic (2023, accessed 4 Apr 2023). https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-convalescent-plasma-potential-promising-covid-19-treatment.
FDA In Transient: FDA updates emergency use authorization for COVID-19 convalescent plasma to replicate new information (2023, accessed 4 Apr 2023). https://www.fda.gov/news-events/fda-brief/fda-brief-fda-updates-emergency-use-authorization-covid-19-convalescent-plasma-reflect-new-data.
COVID-19 Therapy Pointers Panel. COVID-19 Therapy Pointers: COVID-19 Convalescent Plasma (2023, accessed 15 Sep 2023). https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/covid-19-convalescent-plasma/.
Facilities for Illness Management and Prevention. COVID Information Tracker, COVID-19 Vaccinations in america (2023, accessed 3 Mar 2023). https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-people-booster-percent-pop5.
Solar, C., Pleyer, C. & Wiestner, A. COVID-19 vaccines for sufferers with haematological situations. Lancet Haematol. 8, e312–e314. https://doi.org/10.1016/S2352-3026(21)00073-9 (2021).
Herishanu, Y. et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in sufferers with continual lymphocytic leukemia. Blood 137, 3165–3173. https://doi.org/10.1182/blood.2021011568 (2021).
Harvey, R. A. et al. Affiliation of SARS-CoV-2 seropositive antibody take a look at with danger of future an infection. JAMA Intern. Med. 181, 672–679. https://doi.org/10.1001/jamainternmed.2021.0366 (2021).
Biernat, M. M. et al. Early administration of convalescent plasma improves survival in sufferers with hematological malignancies and COVID-19. Viruses 13, 436. https://doi.org/10.3390/v13030436 (2021).
Avouac, J. et al. COVID-19 outcomes in sufferers with inflammatory rheumatic and musculoskeletal ailments handled with rituximab: A cohort research. Lancet Rheumatol. 3, e419–e426. https://doi.org/10.1016/S2665-9913(21)00059-X (2021).
Hensley, M. Ok. et al. Intractable coronavirus illness 2019 (COVID-19) and extended extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in a chimeric antigen receptor-modified T-cell remedy recipient: A case research. Clin. Infect. Dis. 73, e815–e821. https://doi.org/10.1093/cid/ciab072 (2021).
Lancman, G., Mascarenhas, J. & Bar-Natan, M. Extreme COVID-19 virus reactivation following therapy for B cell acute lymphoblastic leukemia. J. Hematol. Oncol. 13, 131. https://doi.org/10.1186/s13045-020-00968-1 (2020).
Hughes, C. M. et al. Scientific sickness with viable extreme acute respiratory coronavirus virus 2 (SARS-CoV-2) virus presenting 72 days after an infection in an immunocompromised affected person. Infect. Management Hosp. Epidemiol. 43, 820–822. https://doi.org/10.1017/ice.2021.120 (2022).
Vardhana, S. A. & Wolchok, J. D. The numerous faces of the anti-COVID immune response. J. Exp. Med. 217, e20200678. https://doi.org/10.1084/jem.20200678 (2020).
Rutherford, M. A. et al. Danger components for extreme outcomes in sufferers with systemic vasculitis and COVID-19: A binational, registry-based cohort research. Arthrit. Rheumatol. 73, 1713–1719. https://doi.org/10.1002/artwork.41728 (2021).
Kim, J. S. et al. Scientific traits and mortality of sufferers with hematologic malignancies and COVID-19: A scientific overview. Eur. Rev. Med. Pharmacol. Sci. 24, 11926–11933. https://doi.org/10.26355/eurrev_202011_23852 (2020).
Vijenthira, A. et al. Outcomes of sufferers with hematologic malignancies and COVID-19: A scientific overview and meta-analysis of 3377 sufferers. Blood 136, 2881–2892. https://doi.org/10.1182/blood.2020008824 (2020).
Sharma, A. et al. Scientific traits and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: An observational cohort research. Lancet Haematol. 8, e185–e193. https://doi.org/10.1016/S2352-3026(20)30429-4 (2021).
Kenig, A., Ishay, Y., Kharouf, F. & Rubin, L. Therapy of B-cell depleted COVID-19 sufferers with convalescent plasma and plasma-based merchandise. Clin. Immunol. 227, 108723. https://doi.org/10.1016/j.clim.2021.108723 (2021).
Hueso, T. et al. Convalescent plasma remedy for B-cell-depleted sufferers with protracted COVID-19. Blood 136, 2290–2295. https://doi.org/10.1182/blood.2020008423 (2020).
Ferrari, S., Caprioli, C., Weber, A., Rambaldi, A. & Lussana, F. Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 sufferers with hematological malignancies. Leuk. Lymphom. 62, 1490–1496. https://doi.org/10.1080/10428194.2021.1872070 (2021).
Thompson, M. A. et al. Affiliation of convalescent plasma remedy with survival in sufferers with hematologic cancers and COVID-19. JAMA Oncol. 7, 1167–1175. https://doi.org/10.1001/jamaoncol.2021.1799 (2021).
Gerber, V. et al. Protracted SARS-CoV-2 pneumonia with rituximab therapy: About two circumstances. J. Med. Virol. 93, 4141–4144. https://doi.org/10.1002/jmv.26921 (2021).
Hamilton, F. W., Lee, T., Arnold, D. T., Lilford, R. & Hemming, Ok. Is convalescent plasma futile in COVID-19? A Bayesian re-analysis of the RECOVERY randomized managed trial. Int. J. Infect. Dis. 109, 114–117. https://doi.org/10.1016/j.ijid.2021.06.034 (2021).
Senefeld, J. W. et al. Use of convalescent plasma in COVID-19 sufferers with immunosuppression. Transfusion 61, 2503–2511. https://doi.org/10.1111/trf.16525 (2021).
Senefeld, J. W. et al. COVID-19 convalescent plasma for the therapy of immunocompromised sufferers: A scientific overview and meta-analysis. JAMA Netw. Open 6, e2250647. https://doi.org/10.1001/jamanetworkopen.2022.50647 (2023).
von Elm, E. et al. The strengthening the reporting of observational research in epidemiology (STROBE) assertion: Pointers for reporting observational research. Equator Community (2023, accessed 18 Jan 2023). https://www.equator-network.org/reporting-guidelines/strobe/.
Tong, A. et al. Core consequence measures for trials in individuals with coronavirus illness 2019: Respiratory failure, multiorgan failure, shortness of breath, and restoration. Crit. Care Med. 49, 503–516. https://doi.org/10.1097/CCM.0000000000004817 (2021).
O’Horo, J. C. et al. Outcomes of COVID-19 with the Mayo Clinic mannequin of care and analysis. Mayo Clin. Proc. 96, 601–618. https://doi.org/10.1016/j.mayocp.2020.12.006 (2021).
O’Shaughnessy, J. Revised Letter of Authorization (2021, accessed 9 Nov 2023). https://www.fda.gov/media/141477/obtain.
Jeny, F. et al. Correspondence on “glucocorticoid-induced relapse of COVID-19 in a affected person with sarcoidosis”. Ann. Rheum. Dis. 81, e241. https://doi.org/10.1136/annrheumdis-2020-218957 (2022).
Kim, M. S., An, M. H., Kim, W. J. & Hwang, T. H. Comparative efficacy and security of pharmacological interventions for the therapy of COVID-19: A scientific overview and community meta-analysis. PLoS Med. 17, e1003501. https://doi.org/10.1371/journal.pmed.1003501 (2020).
Rubio-Rivas, M. et al. WHO ordinal scale and irritation danger classes in COVID-19. Comparative research of the severity scales. J. Gen. Intern. Med. 37, 1980–1987. https://doi.org/10.1007/s11606-022-07511-7 (2022).
R Core Group. R: A language and setting for statistical computing. R Basis for statistical computing, Vienna, Austria (2020, accessed 18 Jan 2023). https://www.R-project.org/.
Smith, J. B., Gonzales, E. G., Li, B. H. & Langer-Gould, A. Evaluation of rituximab use, time between rituximab and SARS-CoV-2 vaccination, and COVID-19 hospitalization or dying in sufferers with a number of sclerosis. JAMA Netw. Open 5, e2248664. https://doi.org/10.1001/jamanetworkopen.2022.48664 (2022).
Levavi, H., Lancman, G. & Gabrilove, J. Influence of rituximab on COVID-19 outcomes. Ann. Hematol. 100, 2805–2812 (2021).
Sales space, S. et al. Key findings from the UKCCMP cohort of 877 sufferers with haematological malignancy and COVID-19: Illness management as an vital issue relative to latest chemotherapy or anti-CD20 remedy. Br. J. Haematol. 196, 892–901 (2021).
McKay, Ok. A. et al. Rituximab infusion timing, cumulative dose, and hospitalization for COVID-19 in individuals with a number of sclerosis in Sweden. JAMA. Netw. Open. 4, e2136697. https://doi.org/10.1001/jamanetworkopen (2021).
Misset, B. et al. Convalescent plasma for Covid-19-induced ARDS in mechanically ventilated sufferers. NEJM 389, 1590–1600 (2023).
Levine, A. C. et al. COVID-19 convalescent plasma outpatient remedy to forestall outpatient hospitalization: A meta-analysis of particular person participant information from 5 randomized trials. Clin. Infect. Dis. 76, 2077–2086 (2023).
Ripoll, J. G. et al. Vaccine-boosted convalescent plasma remedy for sufferers with immunosuppression and COVID-19. Blood Adv. 6, 5951–5955 (2022).
Prepare dinner, L. B. et al. Third major SARS-CoV-2 mRNA vaccines improve antibody responses in most sufferers with haematological malignancies. Nat Commun. 13, 6922. https://doi.org/10.1038/s41467-022-34657-z (2022).
Trottier, C. A. et al. Twin antiviral remedy for persistent coronavirus illness 2019 and related organizing pneumonia in an immunocompromised host. Clin. Infect. Dis. 76, 923–925 (2023).
Ford, E. S. et al. Profitable therapy of extended, extreme coronavirus illness 2019 decrease respiratory tract illness in a B cell acute lymphoblastic leukemia affected person with an prolonged course of remdesivir and nirmatrelvir/ritonavir. Clin. Infect. Dis. 76, 926–929 (2023).
Discover more from PressNewsAgency
Subscribe to get the latest posts sent to your email.